



Firzan Nainu <firzannainu@unhas.ac.id>

Invitation to review for Pharmacological Research - IF 10.334 - [EMID:7c52cab0bb405c73]

1 message

Pharmacological Research <em@editorialmanager.com>
Reply-To: Pharmacological Research <support@elsevier.com>
To: Firzan Nainu <firzannainu@unhas.ac.id>

Wed, Nov 23, 2022 at 10:09 PM

Manuscript Number: YPHRS-D-22-04575

Biomarker discovery and application—an opportunity to resolve the challenge of liver cancer diagnosis and treatment
Jingtao Chen; Chao Niu; Ning Yang; Chunyan Liu; Shanshan Zou; Shan Zhu

Dear Nainu,

We have received a manuscript entitled Biomarker discovery and application—an opportunity to resolve the challenge of liver cancer diagnosis and treatment. We would really appreciate your help in assessing its value, as you are an expert in this area of research. We do hope that you have time to read it for us. You will find that the article is accompanied by a checklist, compiled by the authors and designed to help you in assessing the overall quality of the manuscript. Its use is at your discretion. If the article is a Review Article, the checklist is not mandatory. We also include an "help list" that you may find useful in the overall assessment and that you may also send us with your comments if you so desire.

The manuscript abstract is attached below. If you are willing to review this manuscript, please click on the link below:
<https://www.editorialmanager.com/yphrs/l.asp?i=579513&l=W6F60FCE>

If you are NOT able to review this manuscript, please click on the link below. We would appreciate receiving suggestions for alternative reviewers:
<https://www.editorialmanager.com/yphrs/l.asp?i=579514&l=MFXG7CLD>

If you decline to review I would appreciate your suggestions for alternate reviewers.

We are proud of our fast review process. If you accept this invitation, I would be very grateful if you would return your review within two weeks.

You may submit your comments online at the above URL. There you will find spaces for confidential comments to the editor, comments for the author and a report form to be completed.

Once you submitted your review, you will receive a notification from Elsevier's reviewer recognition platform, which provides you with a link to your "My Elsevier Reviews" private profile page. You can collect your review certificates, editor recognition as well as discounts for Elsevier services from your profile page.

I hope you will be able to review this manuscript.

As a reviewer you are entitled to complimentary access to references, abstracts, and full-text articles on ScienceDirect and Scopus for 30 days. Full details on how to claim your access via Reviewer Hub (reviewerhub.elsevier.com) will be provided upon your acceptance of this invitation to review.

Please visit the Elsevier Reviewer Hub (reviewerhub.elsevier.com) to manage all your refereeing activities for this and other Elsevier journals on Editorial Manager.

Kind regards,

Anita

Anita Bakrania, Ph.D.
Consulting Editor
Pharmacological Research

Abstract:

Liver cancer is one of the most common malignancies, with severe morbidity and mortality. While considerable progress has been made in liver cancer treatment, the 5-year overall survival of patients has not improved significantly. Reasons include the inadequate capability of early screening and diagnosis, a high incidence of recurrence and metastasis, as well as a high degree of tumor heterogeneity, and an immunosuppressive tumor microenvironment. Therefore, the identification and validation of specific and robust liver cancer biomarkers are of major importance for early screening, timely diagnosis, accurate prognosis, and the prevention of tumor progression. In this review, we highlight some of the latest research progress and potential applications of liver cancer biomarkers, describing hotspots and prospective directions in biomarker discovery.

More information and support

FAQ: How do I respond to an invitation to review in Editorial Manager?

https://service.elsevier.com/app/answers/detail/a_id/28524/supporthub/publishing/

You will find guidance and support on reviewing, as well as information including details of how Elsevier recognizes reviewers, on Elsevier's Reviewer Hub: <https://www.elsevier.com/reviewers>

FAQ: How can I reset a forgotten password?

https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/

For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

#REV_YPHRS#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/yphrs/login.asp?a=r>). Please contact the publication office if you have any questions.



Pharmacological Research

Certificate of Reviewing

Awarded since August 2022 (2 reviews)
presented to

FIRZAN NAINU

in recognition of the review contributed to the journal

The Editors of Pharmacological Research

